Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy

CONTEXT: Two tyrosine kinase inhibitors (TKIs), lenvatinib and vandetanib, are often used to treat advanced radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) and medullary thyroid cancer (MTC), respectively. Fatigue is a common adverse event during treatment with these and other TKIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Carla, De Leo, Simone, Di Stefano, Marta, Vannucchi, Guia, Persani, Luca, Fugazzola, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402317/
https://www.ncbi.nlm.nih.gov/pubmed/30383218
http://dx.doi.org/10.1210/jc.2018-01836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402317/
https://www.ncbi.nlm.nih.gov/pubmed/30383218
http://dx.doi.org/10.1210/jc.2018-01836

Ejemplares similares